AnaptysBio (NASDAQ:ANAB) Stock: Insider Ecor1 Capital, Llc Acquires 152,367 Shares

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) Director Ecor1 Capital, Llc acquired 152,367 shares of the stock in a transaction dated Tuesday, November 17th. The stock was acquired at an average cost of $45.66 per share, with a total value of $6,957,077.22. Following the transaction, the director directly owned 8,116,581 shares in the company, valued at approximately $370,603,088.46. This represents a 1.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

  • On Wednesday, November 18th, Ecor1 Capital, Llc purchased 138,093 shares of AnaptysBio stock. The shares were bought at an average cost of $46.54 per share, for a total transaction of $6,426,848.22.
  • On Monday, November 16th, Ecor1 Capital, Llc acquired 84,120 shares of AnaptysBio stock. The shares were acquired at an average price of $45.66 per share, with a total value of $3,840,919.20.

AnaptysBio Stock Up 0.7%

NASDAQ ANAB opened at $47.40 on Friday. The firm’s fifty day simple moving average is $49.02 and its 200-day simple moving average is $56.26. The company has a quick ratio of 8.40, a current ratio of 8.40 and a debt-to-equity ratio of 0.17. AnaptysBio, Inc. has a 1-year low of $22.07 and a 1-year high of $72.36.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The biotechnology company reported $0.11 EPS for the quarter, beating the consensus estimate of ($1.84) by $1.95. AnaptysBio had a negative return on equity of 17.54% and a net margin of 96.30%. The business had revenue of $30.27 million for the quarter, compared to analyst estimates of $25.56 million. Analysts expect that AnaptysBio, Inc. will post -1.30 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ANAB. HC Wainwright reiterated a “buy” rating and set a $95.00 price target on shares of AnaptysBio in a report on Tuesday, September 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of AnaptysBio in a report on Wednesday, November 4th. Scotiabank cut shares of AnaptysBio to a “hold” rating and set a $70.00 price objective on the stock. in a report on Tuesday, August 25th. Leerink Partners dropped their price target on shares of AnaptysBio from $90.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 23rd. Finally, Wall Street Zen cut AnaptysBio from a “buy” rating to a “hold” rating in a report on Sunday, October 4th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $75.67.

Check Out Our Latest Stock Report on ANAB

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Tema ETFs LLC lifted its position in shares of AnaptysBio by 0.6% during the second quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after purchasing an additional 201 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in AnaptysBio by 2.3% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,650 shares of the biotechnology company’s stock worth $887,000 after buying an additional 400 shares in the last quarter. Arizona State Retirement System boosted its stake in AnaptysBio by 13.5% during the 2nd quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock worth $295,000 after acquiring an additional 518 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in AnaptysBio during the 2nd quarter worth about $39,000. Finally, Sterling Capital Management LLC raised its position in shares of AnaptysBio by 847.8% in the third quarter. Sterling Capital Management LLC now owns 654 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 585 shares during the period.

About AnaptysBio

(Get Free Report)

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.

Read More

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.